Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Go back to Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management| (NASDAQ: VANI) | Delayed: 1.39 -0.04 (2.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.43 | 52 Week High | $ | |||
| Open | $1.46 | 52 Week Low | $ | |||
| Day High | $1.48 | P/E | N/A | |||
| Day Low | $1.38 | EPS | $ | |||
| Volume | 296,100 | |||||
